In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Armata Pharmaceuticals (ARMP – Research Report), with a price target of $9.00. The company’s shares closed last Friday at $4.22.
According to TipRanks, Higgins is a 4-star analyst with an average return of 5.8% and a 31.63% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Marinus, Astria Therapeutics, and Zynerba Pharmaceuticals.
Currently, the analyst consensus on Armata Pharmaceuticals is a Moderate Buy with an average price target of $8.00, representing an 89.57% upside. In a report released on August 12, H.C. Wainwright also maintained a Buy rating on the stock with a $7.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $6.49 and a one-year low of $2.82. Currently, Armata Pharmaceuticals has an average volume of 4,149.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.
Read More on ARMP:
- Ladenburg Thalmann & Co. Remains a Buy on Achieve Life Sciences (ACHV)
- MKM Partners Sticks to Its Buy Rating for Cronos Group (CRON)
- These Stocks Are the Biggest Pre-Market Movers on Monday
- atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update
- GreenLight Biosciences Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
